WILMINGTON, Mass., Aug. 6 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc. (Nasdaq GM: DUSA) announces that its corporate highlights and second quarter financial results press release will be issued on Tuesday, August 11 at 6:30 a.m. to be followed by a conference call at 8:30 a.m. Tuesday, August 11 - 8:30 a.m. E.T. If calling from the US or Canada use the following toll-free number: 800.647.4314 Password - DUSA For International callers use 502.498.8422 A recorded replay of the call will be available approximately 15 minutes following the call North American callers 877.863.0350 International callers 858.244.1268 The call will be accessible on our web site approximately four hours following the call at http://www.dusapharma.com/. About DUSA Pharmaceuticals DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan(R) photodynamic therapy (PDT) technology platform, and complementary dermatology products. Levulan(R) PDT is currently approved for the treatment of Grade 1 and 2 actinic keratoses (AKs) of the face and scalp. DUSA also markets other dermatology products, including ClindaReach(R). DUSA is researching Levulan(R) PDT for the treatment of AKs and the reduction of new non-melanoma skin cancer (NMSC) in chronically immunosuppressed solid organ transplant recipients (SOTRs). In addition, DUSA is supporting research related to oral leukoplakia in collaboration with National Institutes of Health (NIH). DUSA is based in Wilmington, Mass. Please visit our Web site at http://www.dusapharma.com/. DATASOURCE: DUSA Pharmaceuticals, Inc. CONTACT: Chad Rubin, The Trout Group LLC, +1-646-378-2947, for DUSA Pharmaceuticals, Inc. Web Site: http://www.dusapharma.com/

Copyright